NCT02484430 2025-03-03
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
1 trialsPrecursor Cell Lymphoblastic Leukemia-Lymphoma × sapanisertib × Other hematologic neoplasm × Clear all